Clinical Trial

Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 9, 2022 (before its estimated July 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human BCMA Targeted T Cells Injection（BCMA CAR-T） Therapy for R/R MM. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of BCMA CAR+ T cells.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-10-21.
Trial Details
NCT Number NCT05594797
Lead Sponsor Hrain Biotechnology Co., Ltd.
Collaborators: Shanghai Changzheng Hospital, First Affiliated Hospital of Wenzhou Medical University
Conditions Multiple Myeloma
Enrollment 100 participants
Start Date 2022-07-12
Primary Completion 2025-07-31 (estimated)
Study Completion 2027-07-31 (estimated)
Updated on ClinicalTrials.gov 2022-12-09